The deletion of SMAD4 (both heterozygous and homozygous deletion) was initially discovered in pancreatic duct adenocarcinoma, followed by its detection in other cancers, like gastric, prostate, or colorectal cancers, albeit at reduced frequency compared to PDAC [1,2]. Here, SMAD4 is linked to cancer.